ArticleRadiation oncology (London, England)2025
Improving total bone marrow and lymphoid irradiation: feasibility of intensity-modulated proton therapy (IMPT) and dosimetric comparison with helical tomotherapy (HT).
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07532824 (Proton Total Marrow Irradiation-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Proton Total Marrow Irradiation-Based Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThis study aims to develop and validate a novel whole-body intensity-modulated proton therapy (IMPT) approach for total marrow/lymphatic irradiation (TMI/TMLI) and compare its efficacy to helical tomotherapy (HT). MATERIALS AND
methodsWhole-body IMPT plans were designed using five isocenters and fifteen fields for adult and three isocenters and eight fields for pediatric. Overlapping sub-PTVs were optimized to ensure robust and homogeneous dose distribution across consecutive isocenters and across CT datasets. Dosimetric benefits were compared to HT, safety and accuracy were verified using an in-house algorithm and planar dosage measurement.
resultsThe average cranio-caudal and lateral whole-body PTV dimensions were 169.24 cm and 46.41 cm for five adults; 95.2 cm and 28.86 cm for one pediatric patient. IMPT plans provided adequate and homogeneous dose to all sub-PTVs, upper and lower body PTVs, with mean D95% ≥ 11.4 GyRBE. In comparison to HT, IMPT plans reduced mean integral dosage to normal tissue by 38%, OARs by a factor of 1.32 to 3.94, and V107% by 520.97 cc for sub-PTVs and 1166 cc for upper-body PTVs. For 38 pairs of planned and measured dosage planes at three depths, the average (± SD) gamma value was 96.77% (± 2.45%). Radiation ON time of 76 and 28 min for the tallest adult and pediatric patient plan was almost double HT plan of 39.9 and 14.1 min.
conclusionThe presented whole-body IMPT approach for TMI/TMLI patients of any physical build-up is dosimetrically superior, safe and feasible to implement. Nevertheless, detailed robustness evaluation and cost-benefit analyses should guide its clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.